ATRA
Income statement / Annual
Last year (2024), Atara Biotherapeutics, Inc.'s total revenue was $128.94 M,
an increase of 1,404.02% from the previous year.
In 2024, Atara Biotherapeutics, Inc.'s net income was -$85.40 M.
See Atara Biotherapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$128.94 M |
$8.57 M |
$63.57 M |
$20.34 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$21.01 M
|
$8.89 M
|
$14.57 M
|
$11.38 M
|
$9.87 M
|
$8.11 M
|
$3.78 M
|
$956,000.00
|
$383,000.00
|
$48,000.00
|
| Gross Profit |
$107.93 M
|
-$313,000.00
|
$49.01 M
|
$8.96 M
|
-$9.87 M
|
-$8.11 M
|
-$3.78 M
|
-$956,000.00
|
-$383,000.00
|
-$48,000.00
|
| Gross Profit Ratio |
0.84
|
-0.04
|
0.77
|
0.44
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$151.48 M
|
$224.79 M
|
$272.53 M
|
$282.00 M
|
$244.65 M
|
$216.10 M
|
$167.46 M
|
$81.21 M
|
$56.51 M
|
$41.62 M
|
| General & Administrative Expenses |
$39.89 M
|
$50.91 M
|
$71.55 M
|
$78.80 M
|
$64.40 M
|
$79.58 M
|
$69.65 M
|
$40.33 M
|
$24.73 M
|
$16.83 M
|
| Selling & Marketing Expenses |
$0.00
|
-$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$39.89 M
|
$49.80 M
|
$71.55 M
|
$78.80 M
|
$64.40 M
|
$79.58 M
|
$69.65 M
|
$40.33 M
|
$24.73 M
|
$16.83 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$700,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$191.37 M
|
$275.69 M
|
$344.09 M
|
$360.80 M
|
$309.05 M
|
$295.68 M
|
$237.11 M
|
$121.53 M
|
$81.24 M
|
$58.45 M
|
| Cost And Expenses |
$212.38 M
|
$284.58 M
|
$344.09 M
|
$360.80 M
|
$309.05 M
|
$295.68 M
|
$237.11 M
|
$121.53 M
|
$81.24 M
|
$58.45 M
|
| Interest Income |
$2.11 M
|
$5.43 M
|
$1.99 M
|
$367,000.00
|
$2.45 M
|
$4.72 M
|
$6.37 M
|
$2.03 M
|
$2.20 M
|
$1.22 M
|
| Interest Expense |
$4.62 M
|
$5.29 M
|
$1.99 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.05 M
|
$4.83 M
|
$14.57 M
|
$11.38 M
|
$9.87 M
|
$8.11 M
|
$3.78 M
|
$956,000.00
|
$383,000.00
|
$48,000.00
|
| EBITDA |
-$83.44 M |
-$266.00 M |
-$213.72 M |
-$331.12 M |
-$296.74 M |
-$282.86 M |
-$233.33 M |
-$120.58 M |
-$80.86 M |
-$58.40 M |
| EBITDA Ratio |
-0.65
|
-31.03
|
-5.2
|
-16.74
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.65
|
-32.19
|
-4.41
|
-16.74
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.98 M
|
-$105,000.00
|
$52.22 M
|
$367,000.00
|
$2.45 M
|
$4.72 M
|
$6.37 M
|
$2.03 M
|
$2.20 M
|
$1.22 M
|
| Income Before Tax |
-$85.42 M
|
-$276.11 M
|
-$228.29 M
|
-$340.10 M
|
-$306.61 M
|
-$290.96 M
|
-$230.74 M
|
-$119.51 M
|
-$79.04 M
|
-$57.23 M
|
| Income Before Tax Ratio |
-0.66
|
-32.21
|
-3.59
|
-16.72
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$12,000.00
|
$15,000.00
|
$12,000.00
|
$46,000.00
|
$15,000.00
|
$12,000.00
|
-$44,000.00
|
-$14,000.00
|
$10,000.00
|
-$9,000.00
|
| Net Income |
-$85.40 M
|
-$276.13 M
|
-$2.28 B
|
-$3.40 B
|
-$3.07 B
|
-$2.91 B
|
-$2.31 B
|
-$1.19 B
|
-$790.49 M
|
-$572.21 M
|
| Net Income Ratio |
-0.66
|
-32.21
|
-35.91
|
-167.23
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-11.41 |
-65.18 |
-55.96 |
-90.78 |
-103.63 |
-141.78 |
-131.64 |
-100.03 |
-68.78 |
-55.92 |
| EPS Diluted |
-11.41 |
-65.18 |
-55.96 |
-90.78 |
-103.63 |
-141.78 |
-131.64 |
-100.03 |
-68.78 |
-55.92 |
| Weighted Average Shares Out |
$7.49 M
|
$4.24 M
|
$4.08 M
|
$3.75 M
|
$2.96 M
|
$2.05 M
|
$1.75 M
|
$1.19 M
|
$1.15 M
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$7.49 M
|
$4.24 M
|
$4.08 M
|
$3.75 M
|
$2.96 M
|
$2.05 M
|
$1.75 M
|
$1.19 M
|
$1.15 M
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
